Table 4. Efficacy data by type of retroperitoneal sarcoma.
| RST | CR | PR | SD | PD | ORR (%) |
|---|---|---|---|---|---|
| Liposarcoma | 1 | 3 | 22 | 4 | 13.3 |
| WDLPS | 0 | 0 | 12 | 1 | 0.0 |
| DDLPS | 1 | 2 | 9 | 2 | 21.4 |
| MLS | 0 | 1 | 1 | 0 | 50.0 |
| PLS | 0 | 0 | 0 | 1 | 0.0 |
| Leiomyosarcoma | 0 | 1 | 3 | 4 | 12.5 |
| Rhabdomyosarcoma | 0 | 2 | 1 | 0 | 66.7 |
| Fibrosarcoma | 0 | 0 | 1 | 1 | 0.0 |
| Aggressive fibromatosis | 0 | 0 | 2 | 0 | 0.0 |
| DSRCT | 0 | 1 | 1 | 0 | 50.0 |
| MPNST | 1 | 0 | 0 | 1 | 50.0 |
| SMFT | 0 | 1 | 1 | 0 | 50.0 |
| UPS | 0 | 1 | 0 | 0 | 100.0 |
| Synovial sarcoma | 0 | 1 | 0 | 0 | 100.0 |
| Malignant paraganglioma | 0 | 1 | 0 | 0 | 100.0 |
| High-grade sarcomas (NOS) | 0 | 2 | 0 | 1 | 66.7 |
RST, retroperitoneal soft tissue sarcoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; MLS, myxoid liposarcoma; PLS, pleomorphic liposarcoma; DSRCT, desmoplastic small round cell tumor; MPNST, malignant peripheral nerve sheath tumor; SMFT, solitary malignant fibrous tumor; UPS, undifferentiated pleomorphic sarcoma; NOS, not otherwise specified.